A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma.

Cancer Immunol Immunother · 2019 · PMC6447692 · PMID 30725205

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

a clear trendp = 0.059so close (0.05 < p ≤ 0.1)

The Dermatologic Cooperative Oncology Group (DeCOG) trial demonstrated durable improvement in both RFS and OS [ 29 ], while the French Cooperative Group trial demonstrated significant extension of RFS and a clear trend towards increased overall survival ( p = 0.059) [ 30 ].

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.